Inequities in access to biologic and synthetic DMARDs across 46 European countries

Polina Putrik, Sofia Ramiro, Tore K. Kvien, Tuulikki Sokka, Milena Pavlova, Till Uhlig, Annelies Boonen, Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe'

Research output: Contribution to journalArticleResearchpeer-review

Abstract

Objectives We investigated access to biologic and synthetic disease modifying drugs (bDMARDs and sDMARDs) in patients with rheumatoid arthritis (RA) across Europe. Methods A cross-sectional study at national level was performed in 49 European countries. A questionnaire was sent to one expert, addressing the number of approved and reimbursed bDMARDs and sDMARDs, prices and copayments, as well as acceptability of bDMARDs (barriers). Data on socio-economic welfare (gross domestic product per capita (GDP), health expenditure, income) were retrieved from web-based sources. Data on health status of RA patients were retrieved from an observational study. Dimensions of access (availability, affordability and acceptability) were correlated with the country's welfare and RA health status. Results In total, 46 countries (94%) participated. Six countries did not reimburse any of the five sDMARDs surveyed, and in ten countries no bDMARDs were reimbursed. While the price of annual treatment with an average sDMARD was never higher than GPD, the price of one year treatment with a bDMARD exceeded GPD in 26 countries. Perceived barriers for access to bDMARDs were mainly found among financial and administrative restrictions. All dimensions of access were positively correlated with the country's economic welfare (coefficients 0.69 to 0.86 for overall access scores). Conclusions Patients with RA in lower income European countries have less access to bDMARDs and sDMARDs, with particularly striking unaffordability of bDMARDs in some of these countries. When accepting that sDMARDs and bDMARDs are equally needed across countries to treat RA, our data point to inequities in access to pharmacological treatment for RA in Europe.

Original languageEnglish
Pages (from-to)198-206
Number of pages9
JournalAnnals of the Rheumatic Diseases
Volume73
Issue number1
DOIs
Publication statusPublished - 1 Jan 2014
Externally publishedYes

Cite this

Putrik, P., Ramiro, S., Kvien, T. K., Sokka, T., Pavlova, M., Uhlig, T., Boonen, A., & Working Group 'Equity in access to treatment of rheumatoid arthritis in Europe' (2014). Inequities in access to biologic and synthetic DMARDs across 46 European countries. Annals of the Rheumatic Diseases, 73(1), 198-206. https://doi.org/10.1136/annrheumdis-2012-202603